Occlusive treatment in psoriasis: How does it work? [3]

Journal of the American Academy of Dermatology

Volumn 35, Issue 2 I, 1996, Pages 283-284

  Lotti, T ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CORTICOSTEROID; DITHRANOL; METHOXSALEN; PLASMINOGEN ACTIVATOR;

ANTIBODY PRODUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; LETTER; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PSORIASIS; STEROID THERAPY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; WOUND DRESSING;

EID: 0029742339     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(96)90360-6     Document Type: Letter

References (5)

1. JE Fraki GS Lazarus RS Gilgor Correlation of epidermal plasminogen activator activity with disease activity in psoriasis Br J Dermatol 108 1983 39 44
2. T Lotti P Bonan E Panconesi Epidermal plasminogen activator activity, tPA-dependent, is a marker of disease activity in psoriasis J Invest Dermatol 90 1988 86 87
3. T Lotti L Brunetti E Panconesi A “novel” action of anthralin (letter) Arch Dermatol 122 1986 748 749
4. T Lotti P Bonan G Cannarozzo Antipsoriatic therapies inhibit epidermal plasminogen activator activity Int J Dermatol 7 1990 528 530
5. T Lotti P Bonan E Panconesi Plasminogen activation in psoriasis Acta Derm Venereol (Stockh) Suppl 146 1989 36 38